BriaCell Prices $4.7 Million Offering Of Shares; Stock Down

BriaCell Therapeutics priced a public offering of 1.45 million shares at $3.25 per share. The news is a routine capital-raising event for the clinical-stage biotech company and provides funding, but it is not otherwise operationally significant. The announcement is likely to have limited market impact beyond dilution concerns.

Analysis

BriaCell Therapeutics priced a public offering of 1.45 million shares at $3.25 per share. The news is a routine capital-raising event for the clinical-stage biotech company and provides funding, but it is not otherwise operationally significant. The announcement is likely to have limited market impact beyond dilution concerns.